Idera, Inc.

Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines

Retrieved on: 
Wednesday, June 28, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Beth Israel Deaconess Medical Center, SAB, Idera, Inc., Partnership, Central nervous system, University, University of Massachusetts, Therapy, Oxford, Schering-Plough, Therapeutic index, Oligonucleotide, ATX, RNA, IP, Antibody, Doctor of Philosophy, CNS, TCR, UCB, Patient, Peptide, Medicine, Biology, Liver, Merck, Ecosystem, Rare, Immunology, TLR, Alloy, Gene, Fine chemical, Vaccine, Pharmaceutical industry, Chemistry

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
  • Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC.
  • “The AntiClastic format has the potential to transform the development of antisense therapeutics,” said Agrawal.
  • In launching the AntiClastic ASO platform, Alloy is expanding into its third biologic modality, genetic medicines.

bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer

Retrieved on: 
Monday, May 1, 2023
Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Russell Investments, Certified Public Accountant, American Institute of Certified Public Accountants, BIAF, Lung, Human voice, Amazon, Diagnosis, Financial management, American Institute, Idera, Inc., Management

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael Dougherty has joined the company as Chief Financial Officer, effective today.
  • Mr. Dougherty will report directly to bioAffinity Technologies President and Chief Executive Officer Maria Zannes.
  • Previously, Mr. Dougherty was Chief Financial and Operating Officer of TINT, a user-generated content platform, and Chief Financial Officer at Filestack, a secure file handling service provider that was acquired by Idera, Inc.
  • Prior to that, Mr. Dougherty served as Chief Financial Officer for Amazon Pay, where he supported Amazon’s digital payment wallet globally.

Aparavi Increases Sales and Marketing Presence with Addition of Two Industry Leaders

Retrieved on: 
Tuesday, April 18, 2023
Data Management, Security, Technology, Software, Networks, Internet, Data management, Tailent Automation Platform, Software as a service, Veritas Technologies, ROT, Marketing, Pervasive Software, ROMI, Actian, Automation, Organization, Fortune 500, Idera, Inc., Gladden, Knowledge, OEM, Cryptocurrency, Management, Sitecore

Aparavi , the company behind the award-winning Aparavi Data Intelligence and Automation Platform, today announced the hiring of Jerrod Gladden as its new vice president of sales and marketing and Barry Kunst as director of marketing.

Key Points: 
  • Aparavi , the company behind the award-winning Aparavi Data Intelligence and Automation Platform, today announced the hiring of Jerrod Gladden as its new vice president of sales and marketing and Barry Kunst as director of marketing.
  • Gladden comes to Aparavi from Kyvos Insights Inc. where he served as vice president of sales.
  • Prior to Sitecore, he served as director of marketing operations at Veritas Technologies, won multiple awards on ROMI for marketing tech achievements.
  • Barry was also a senior manager of marketing at Broadcom Software and the Americas field marketing owning the FICO.com website.

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

Retrieved on: 
Tuesday, January 17, 2023
Disease, TERRA, Valencia CF Foundation, United Kingdom, Infection, QIDP, ASAH1, Cystic fibrosis, DMC, Rheumatology, Enzyme replacement therapy, Series, Organic acid, Trial of the century, FDA, Melioidosis, Joint, Immune system, Partnership, Central nervous system, Degenerative disease, Patient, CF, Inflammation, Cartilage, Orphan drug, Farber disease, Idera, Inc., Optimism, Life, TDN, Pharmaceutical industry, Food delivery

DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. (“Aceragen,” the “Company,” “we,” “us,” or “our”) and “ACGN”. Additionally, the Company’s stockholders approved the conversion into common stock of the Series Z preferred shares resulting from the previously announced merger with Aceragen and authorized a reverse split of common stock. The Company’s Board of Directors has approved the reverse stock split at a ratio of 1-for-17 shares. As a result of these changes, which will be effective upon the market open on Wednesday, January 18, 2023, the Company will be in compliance with all applicable Nasdaq listing standards. Nasdaq has issued an approval letter confirming Aceragen’s listing.

Key Points: 
  • The Company’s Board of Directors has approved the reverse stock split at a ratio of 1-for-17 shares.
  • “We are excited to have completed the transformation of Aceragen via our merger with Idera and the subsequent adjustments to our stock and Nasdaq listing.
  • Aceragen has a portfolio of late-stage clinical assets in cystic fibrosis and Farber disease with clinical milestones anticipated in 2023.
  • Due to the ultra-rare nature of Farber disease, if successful, this study has the potential to support registration of the product.

Global Augmented Analytics Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Retrieved on: 
Tuesday, January 17, 2023
Microsoft, Qlik, Idera, Inc., ML, COVID-19, Machine learning, SE, Travel, Tourism, AI, Organization, SAP SE, Marketing, Artificial intelligence, IBM, Oracle Corporation, Data science, Traction, SAP, Health, Medical device, Potash, Growth

DUBLIN, Jan. 17, 2023 /PRNewswire/ -- The "Augmented Analytics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 17, 2023 /PRNewswire/ -- The "Augmented Analytics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global augmented analytics market size reached US$ 8.27 Billion in 2021.
  • Key Questions Answered in This Report:
    How has the global augmented analytics market performed so far and how will it perform in the coming years?
  • What is the structure of the global augmented analytics market and who are the key players?

BackBox Reinforces Focus on Network Security Automation with Launch of Managed Service Provider Program and Key Executive Hires

Retrieved on: 
Tuesday, August 16, 2022
Data Management, Security, Technology, Software, Networks, Internet, MSSP, MSP, RSA, Member of the Scottish Parliament, Risk, INS, CEO, Idera, Inc., Super Mario, International Network Services Inc., Salesforce, Air force, Technology, Growth, Security company, Computer security, Service provider, Compliance, Managed services, Network administrator, SolarWinds, Partnership, CTO, Automation, Organization, Culture, ActivTrak (software), Airport, United, Health, Management, Risk management, Online shopping, Oracle, Google, BackBox

BackBox , a leading provider in network automation, security and management, today announced an enhanced focus on solving network security challenges via automation with two key executive hires and the launch of a formal Managed Service Provider (MSP) and Managed Security Services Provider (MSSP) Program.

Key Points: 
  • BackBox , a leading provider in network automation, security and management, today announced an enhanced focus on solving network security challenges via automation with two key executive hires and the launch of a formal Managed Service Provider (MSP) and Managed Security Services Provider (MSSP) Program.
  • MSPs and MSSPs play an important role in our network security automation strategy because smaller companies generally dont have a dedicated network engineer or access to the talent needed to automate network capabilities.
  • Small and medium businesses (SMBs) have few options when it comes to network security, and therefore outsource network security to MSSPs, Kahl continued.
  • To learn more about BackBoxs leading network security automation solutions or inquire about becoming a BackBox partner, please visit www.backbox.com .

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Securities Act of 1933, Idera, Inc., GLOBE, Securities Exchange Act of 1934, Security (finance), Nasdaq, COVID-19, Company, Acquisition, Coronavirus, Intention, Research, Food, Disease

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.

Key Points: 
  • EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.
  • Our cash position as of June 30, 2022 was $24.5 million.
  • Research and development expenses for the three months ended June 30, 2022 totaled $2.7 million, compared to $3.9 million for the same period in 2021.
  • General and administrative expense for the three months ended June 30, 2022 totaled $2.7 million, compared to $2.5 million for the same period in 2021.

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

Retrieved on: 
Tuesday, May 17, 2022
Cancer, U.S. Securities and Exchange Commission, Risk, Fever, Company, Flow cytometry, Disease, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, OS, Survival, Melanoma, Nasdaq, Patient, Coronavirus, Phase II, Sentinel lymph node, SLN, LNR, Clinical trial, Idera, Inc., Survival rate, COVID-19, UMC, Death, Antigen presentation, Hope, Recurrence, Securities Act of 1933, Securities Exchange Act of 1934, Intention, Partnership, TLR9, Vrije Universiteit Amsterdam, B cell, Justice and Security Act 2013, Biopsy, Skin, Acquisition, GLOBE, RFS, Melanocyte, Security (finance), Documentation, Pharmaceutical industry, Medical imaging, Vaccine

EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, we, and our) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist.

Key Points: 
  • EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, we, and our) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist.
  • The trial will continue to relapse-free survival (RFS) and overall survival (OS) at 5 and 10 years after SLN biopsy.
  • Currently, there are limited adjuvant treatments available to improve survival after surgical excision of a primary melanoma, said Prof. Tanja de Gruijl of Amsterdam UMC.
  • INTRIM 1 is a multi-center investigator-sponsored trial conducted by UMC Amsterdam among patients with pT3-4 cN0M0 melanoma.

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Nasdaq, GLOBE, Company, Securities Exchange Act of 1934, Securities Act of 1933, Food, Research, Idera, Inc., Security (finance), Coronavirus, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Intention, Disease, Net, Acquisition, Bank, Online gambling

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022.

Key Points: 
  • EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022.
  • Our cash position as of March 31, 2022 was $28.0 million.
  • Research and development expenses for the three months ended March 31, 2022 totaled $1.8 million, compared to $6.9 million for the same period in 2021.
  • General and administrative expense for the three months ended March 31, 2022 totaled $2.4 million, compared to $3.2 million for the same period in 2021.

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 31, 2022
Company, Coronavirus, Nasdaq, Research, Food, Â, Security (finance), Intention, Securities Exchange Act of 1934, Securities Act of 1933, COVID-19, U.S. Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, Idera, Inc., GLOBE, Annual report, Acquisition, Disease, Annual, Risk management, Online gambling, Cryptocurrency

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, or our) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021.
  • Our cash position as of December 31, 2021 was $32.5 million.
  • General and administrative expense for the three months ended December 31, 2021 totaled $2.0 million, compared to $2.9 million for the same period in 2020.
  • No such non-cash losses were recognized in the three months ended December 31, 2021, as the warrants and future tranche rights were terminated in the first quarter of 2021.